India, July 22 -- Novo Nordisk A/S sued Eli Lilly & Co., accusing its rival of misleading advertising as competition in the US market for obesity drugs ratchets up further. Novo says that Lilly's advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo's own obesity shot Wegovy than what's currently available, according to the complaint. Though Lilly's Zepbound beat Wegovy in a head-to-head trial last year, Novo subsequently got approval for a higher dose of its drug than what was used in that study. mint...